

Pharmacy Quality Scheme 2023/24:

Bulletin 1 - Respiratory & Prevention Domain

Details of the Pharmacy Quality Scheme 2023/24 are now available to read via the **NHSBSA** website here.

More details and advice will be emailed out as standalone numbered PQS bulletins in due course but for the moment, please note that elements of the **RESPIRATORY DOMAIN** require contractors to begin holding conversations with patients and be able to 'evidence' that those conversations have taken place, from **1st June 2023**.



Inhaler Waste Management - the pharmacy must be able to evidence that they have spoken with all patients, their carer or representatives, for whom they have dispensed an inhaler between **1st June 2023** and the day of the declaration, about the environmental benefits of them returning all unwanted and used inhaler devices to a community pharmacy for disposal.

Use of a Spacer in Patients Aged 5-15 Years - the pharmacy must be able to evidence that between 1st June 2023 and the day of the declaration they have:

- Checked that all children aged 5 to 15 prescribed a press and breathe pressurised
 MDI for asthma have a spacer device, where appropriate and
- Referred children aged 5 to 15 with asthma to an appropriate healthcare professional where this is not the case.

Personalised Asthma Action Plans (PAAP) - the pharmacy must be able to evidence that they have checked that all patients aged five years and above dispensed an inhaler for asthma between **1st June 2023** and the day of the declaration have a PAAP and show that pharmacy staff have referred all patients aged five years and above dispensed an inhaler for asthma between **1st June 2023** and the day of the declaration to an appropriate healthcare professional where this is not the case.

Referrals for Patients Using 3 or More Short-Acting Bronchodilator Inhalers in 6 months - the pharmacy must be able to evidence that between 1st June 2023 and the day of the declaration that patients with asthma, for whom three or more short-acting bronchodilator inhalers were dispensed without any corticosteroid inhaler within a sixmonth period have, since the last review point, been referred to an appropriate healthcare professional for an asthma review.

Prevention - Antimicrobial Stewardship - the pharmacy must be able to evidence they have spoken with all patients, their carer or representative, for whom they have dispensed antibiotics between **1st June 2023** and the day of the declaration, about the benefits of them returning all unwanted antibiotics to a community pharmacy for safe and environmentally friendly disposal.

If you have any questions, please contact Phil Wiles using email <u>pcnsupport@cpwy.org</u> or mobile 07793 218 060.

Kind regards,